{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:22:13Z","timestamp":1788391333517,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The global incidence of invasive pneumococcal disease (IPD) decreased after the switch from PCV7 to PCV13 in 2010. However, serotype 3 remains the leading cause of IPD in Catalonia (Spain), due to the low effectiveness of PCV13 against it. This study aimed to analyze the clinical, epidemiological, and microbiological characteristics of IPD in children over 5\u00a0years and evaluate the potential impact of new vaccines (PCV15 and PCV20). A 5-year prospective observational study was conducted from 2018 to 2022, including children up to 18 hospitalized with IPD at three major children\u2019s hospitals in Catalonia. Data on clinical, epidemiological, and microbiological factors were collected. A total of 220 episodes were identified, with a median age of 33.0\u00a0months (range 0\u2013209). Comparing pre-pandemic (2018\u20132019) to early pandemic years (2020\u20132021), the IPD rate in children\u2009&lt;\u200918\u00a0years decreased by 60.6% (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). However, no significant change was observed when comparing 2022 to 2018. The most common diagnoses were pneumonia (61.8%), meningitis (14.5%), and bacteremia without focus (13.2%). Serotype 3 was the leading cause (35.1%) of IPD and was associated with complicated pneumonia (84.7%) and vaccine failure (73.6%). Ninety-three IPD episodes (45.4%) were caused by PCV13 serotypes, 97 (47.3%) by PCV15 serotypes, and 132 (64.4%) by PCV20 serotypes.\n                    <jats:italic>Conclusion<\/jats:italic>\n                    : The incidence of IPD has remained stable, except for a decrease during the pandemic. Serotype 3 was the most common, often associated with vaccine failures and severe pneumonia. PCV15 and PCV20 vaccines could offer better coverage against circulating serotypes and further reduce IPD incidence in Catalonia.\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>What is Known:<\/jats:bold>\n                              <jats:italic>\u2022 Serotype 3 remains a leading cause of invasive pneumococcal disease (IPD) despite inclusion in PCV13 due to its limited vaccine effectiveness.<\/jats:italic>\n                              <jats:italic>\u2022 IPD incidence decreased globally during the COVID-19 pandemic, likely due to public health measures.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>What is New:<\/jats:bold>\n                              <jats:italic>\u2022 In Catalonia, serotype 3 continues to dominate pediatric IPD cases and is frequently associated with complicated pneumonia and vaccine failure.<\/jats:italic>\n                              <jats:italic>\u2022 PCV15 and PCV20 offer broader serotype coverage and may significantly improve IPD prevention in children.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s00431-025-06137-1","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T18:06:24Z","timestamp":1746209184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018\u20132022"],"prefix":"10.1007","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3104-675X","authenticated-orcid":false,"given":"Mariona F.","family":"de Sevilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6269-0268","authenticated-orcid":false,"given":"Claudia","family":"Alcaraz-Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1353-5325","authenticated-orcid":false,"given":"Nuria","family":"Soldevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2611-6055","authenticated-orcid":false,"given":"Conchita","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7133-4540","authenticated-orcid":false,"given":"Cristina","family":"Esteva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7449-2632","authenticated-orcid":false,"given":"Fernando","family":"Moraga-Llop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8186-8669","authenticated-orcid":false,"given":"Sebasti\u00e0","family":"Gonz\u00e1lez-Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0842-7220","authenticated-orcid":false,"given":"Pilar","family":"Ciruela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0631-3142","authenticated-orcid":false,"given":"Alvaro","family":"D\u00edaz-Conradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaresh","family":"P\u00e9rez-Arg\u00fcello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Vi\u00f1ado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0219-1907","authenticated-orcid":false,"given":"Angela","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3483-528X","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5586-404X","authenticated-orcid":false,"given":"Carmen","family":"Mu\u00f1oz-Almagro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"6137_CR1","doi-asserted-by":"crossref","unstructured":"Wahl B, O\u2019brien KL, Greenbaum A, et al (2018) Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u201315, www.thelancet.com\/lancetgh","DOI":"10.1016\/S2214-109X(18)30247-X"},{"key":"6137_CR2","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","volume":"400","author":"KS Ikuta","year":"2022","unstructured":"Ikuta KS, Swetschinski LR, Aguilar GR et al (2022) Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet 400:2221\u20132248","journal-title":"The Lancet"},{"key":"6137_CR3","doi-asserted-by":"crossref","unstructured":"Ganaie F, Maruhn K, Li C et al (2021) Structural, genetic, and serological elucidation of Streptococcus pneumoniae serogroup 24 serotypes: discovery of a new serotype, 24C, with a variable capsule structure. J Clin Microbiol 59","DOI":"10.1128\/JCM.00540-21"},{"key":"6137_CR4","doi-asserted-by":"crossref","unstructured":"Tin Tin Htar M, Christopoulou D, Schmitt HJ (2015) Pneumococcal serotype evolution in Western Europe. BMC Infect Dis 15","DOI":"10.1186\/s12879-015-1147-x"},{"key":"6137_CR5","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1128\/CVI.00239-13","volume":"20","author":"J Picazo","year":"2013","unstructured":"Picazo J, Ruiz-Contreras J, Casado-Flores J et al (2013) Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid Spain. Clin Vaccine Immunol 20:1524\u20131530","journal-title":"Clin Vaccine Immunol"},{"key":"6137_CR6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1086\/524660","volume":"46","author":"C Mu\u00f1oz-Almagro","year":"2008","unstructured":"Mu\u00f1oz-Almagro C, Jordan I, Gene A et al (2008) Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 46:174\u2013182","journal-title":"Clin Infect Dis"},{"key":"6137_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/INF.0b013e318241d09e","volume":"31","author":"MF de Sevilla","year":"2012","unstructured":"de Sevilla MF, Garc\u00eda-Garc\u00eda J-J, Esteva C et al (2012) Clinical presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine. Pediatric Infectious Dis J 31:124\u2013128","journal-title":"Pediatric Infectious Dis J"},{"key":"6137_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3201\/eid2801.210734","volume":"28","author":"G Hanquet","year":"2022","unstructured":"Hanquet G, Krizova P, Dalby T et al (2022) Serotype replacement after introduction of 10-valent and 13-valent pneumococcal conjugate vaccines in 10 countries Europe. Emerg Infect Dis 28:137\u2013138","journal-title":"Emerg Infect Dis"},{"key":"6137_CR9","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1016\/j.vaccine.2019.06.071","volume":"37","author":"N Andrews","year":"2019","unstructured":"Andrews N, Kent A, Amin-Chowdhury Z et al (2019) Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006\u20132018. Vaccine 37:4491\u20134498","journal-title":"Vaccine"},{"key":"6137_CR10","doi-asserted-by":"crossref","unstructured":"Dom\u00ednguez \u00c1, Ciruela P, Hern\u00e1ndez S et al (2017) Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7\u201359 months A matched case-control study. PLoS One 12:e0183191","DOI":"10.1371\/journal.pone.0183191"},{"key":"6137_CR11","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.3201\/eid2811.211741","volume":"28","author":"P Ciruela","year":"2022","unstructured":"Ciruela P, Soldevila N, Garc\u00eda-Garcia JJ et al (2022) Effect of COVID-19 pandemic on invasive pneumococcal disease in children, Catalonia Spain. Emerg Infect Dis 28:2321\u20132325","journal-title":"Emerg Infect Dis"},{"key":"6137_CR12","unstructured":"Brueggemann AB, Jansen van Rensburg MJ, Shaw D et al (2021) Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data, www.thelancet.com\/digital-health"},{"key":"6137_CR13","doi-asserted-by":"crossref","unstructured":"Izquierdo C, Ciruela P, Soldevila N et al (2023) Changes in invasive pneumococcal disease in the paediatric population in the second COVID-19 pandemic year. Vaccines (Basel) 11","DOI":"10.3390\/vaccines11101548"},{"key":"6137_CR14","doi-asserted-by":"publisher","first-page":"e582","DOI":"10.1016\/S2589-7500(23)00108-5","volume":"5","author":"D Shaw","year":"2023","unstructured":"Shaw D, Abad R, Amin-Chowdhury Z et al (2023) Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium. Lancet Digit Health 5:e582\u2013e593","journal-title":"Lancet Digit Health"},{"key":"6137_CR15","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1016\/j.vaccine.2023.04.036","volume":"41","author":"F Martinon-Torres","year":"2023","unstructured":"Martinon-Torres F, Wysocki J, Szenborn L et al (2023) A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1). Vaccine 41:3387\u20133398","journal-title":"Vaccine"},{"key":"6137_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.vaccine.2021.08.049","volume":"40","author":"HL Platt","year":"2022","unstructured":"Platt HL, Cardona JF, Haranaka M et al (2022) A phase 3 trial of safety, tolerability, and immunogenicity of V. 114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine 40:162\u2013172","journal-title":"Vaccine"},{"key":"6137_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/14760584.2023.2294153","volume":"23","author":"TJ Chapman","year":"2024","unstructured":"Chapman TJ, Olarte L, Dbaibo G et al (2024) PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children. Expert Rev Vaccines 23:137\u2013147","journal-title":"Expert Rev Vaccines"},{"key":"6137_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/cid\/ciab990","volume":"75","author":"B Essink","year":"2022","unstructured":"Essink B, Sabharwal C, Cannon K et al (2022) Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years. Clin Infect Dis 75:390\u2013398","journal-title":"Clin Infect Dis"},{"key":"6137_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/INF.0000000000004334","volume":"43","author":"S Senders","year":"2024","unstructured":"Senders S, Klein NP, Tamimi N et al (2024) A phase three study of the safety and immunogenicity of a four-dose series of 20-valent pneumococcal conjugate vaccine in healthy infants. Pediatric Infect Dis J 43:596\u2013603","journal-title":"Pediatric Infect Dis J"},{"key":"6137_CR20","unstructured":"Institut d\u2019Estad\u00edstica de Catalunya. https:\/\/www.idescat.cat\/. Accessed 13 Aug 2024."},{"key":"6137_CR21","unstructured":"Conjunt m\u00ednim b\u00e0sic de dades (CMBD). CatSalut. Servei Catal\u00e0 de la Salut., https:\/\/catsalut.gencat.cat\/ca\/proveidors-professionals\/registres-catalegs\/registres\/cmbd\/ (accessed 13 August 2024)."},{"key":"6137_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.diagmicrobio.2007.12.011","volume":"61","author":"C Kee","year":"2008","unstructured":"Kee C, Palladino S, Kay I et al (2008) Feasibility of real-time polymerase chain reaction in whole blood to identify Streptococcus pneumoniae in patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 61:72\u201375","journal-title":"Diagn Microbiol Infect Dis"},{"key":"6137_CR23","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1128\/JCM.00906-14","volume":"52","author":"L Selva","year":"2014","unstructured":"Selva L, Berger C, Garcia-Garcia JJ et al (2014) Direct identification of Streptococcus pneumoniae capsular types in pleural fluids by using multiplex PCR combined with automated fluorescence-based capillary electrophoresis. J Clin Microbiol 52:2736\u20132737","journal-title":"J Clin Microbiol"},{"key":"6137_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.vaccine.2011.12.048","volume":"30","author":"U Heininger","year":"2012","unstructured":"Heininger U, Bachtiar NS, Bahri P et al (2012) The concept of vaccination failure. Vaccine 30:1265\u20131268","journal-title":"Vaccine"},{"key":"6137_CR25","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics (2000) Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 106: 362\u2013366.","DOI":"10.1542\/peds.106.2.362"},{"key":"6137_CR26","doi-asserted-by":"crossref","unstructured":"Redin A, Ciruela P, de Sevilla MF et al (2021) Serotypes and clonal composition of Streptococcus pneumoniae isolates causing IPD in children and adults in Catalonia before 2013 to 2015 and after 2017 to 2019 systematic introduction of PCV13. Microbiol Spectr 9","DOI":"10.1128\/Spectrum.01150-21"},{"key":"6137_CR27","doi-asserted-by":"crossref","unstructured":"Henares D, Lo SW, Perez-Arg\u00fcello A et al (2023) Comparison of next generation technologies and bioinformatics pipelines for capsular typing of Streptococcus pneumoniae. J Clin Microbiol 61","DOI":"10.1128\/jcm.00741-23"},{"key":"6137_CR28","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/j.1469-0691.2008.02028.x","volume":"14","author":"D Tarrag\u00f3","year":"2008","unstructured":"Tarrag\u00f3 D, Fenoll A, S\u00e1nchez-Tatay D et al (2008) Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR. Clin Microbiol Infect 14:828\u2013834","journal-title":"Clin Microbiol Infect"},{"key":"6137_CR29","unstructured":"European Committee on Antimicrobial Susceptibility Testing. https:\/\/www.eucast.org\/newsiandr. Accessed 13 Aug 2024"},{"key":"6137_CR30","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1128\/JB.186.5.1518-1530.2004","volume":"186","author":"EJ Feil","year":"2004","unstructured":"Feil EJ, Li BC, Aanensen DM et al (2004) eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol 186:1518\u20131530","journal-title":"J Bacteriol"},{"key":"6137_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.anpede.2021.06.005","volume":"96","author":"J Mart\u00ednez-Osorio","year":"2022","unstructured":"Mart\u00ednez-Osorio J, Garc\u00eda-Garc\u00eda JJ, Moraga-Llop F et al (2022) Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine. Anales de Pediatr\u00eda (English Edition) 96:501\u2013510","journal-title":"Anales de Pediatr\u00eda (English Edition)"},{"key":"6137_CR32","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3201\/eid2808.220304","volume":"28","author":"M Bertran","year":"2022","unstructured":"Bertran M, Amin-Chowdhury Z, Sheppard CL et al (2022) Increased incidence of invasive pneumococcal disease among children after COVID-19 pandemic England. Emerg Infect Dis 28:1669\u20131672","journal-title":"Emerg Infect Dis"},{"key":"6137_CR33","doi-asserted-by":"publisher","first-page":"106204","DOI":"10.1016\/j.jinf.2024.106204","volume":"89","author":"C P\u00e9rez-Garc\u00eda","year":"2024","unstructured":"P\u00e9rez-Garc\u00eda C, Sempere J, de Miguel S et al (2024) Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019\u20132023). J Infect 89:106204","journal-title":"J Infect"},{"key":"6137_CR34","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1128\/JCM.36.3.669-673.1998","volume":"36","author":"R Dagan","year":"1998","unstructured":"Dagan R, Shriker O, Hazan I et al (1998) Prospective study to determine clinical relevance of detection of pneumococcal DNA in sera of children by PCR. J Clin Microbiol 36:669\u2013673","journal-title":"J Clin Microbiol"},{"key":"6137_CR35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1099\/jmm.0.028357-0","volume":"60","author":"C Azzari","year":"2011","unstructured":"Azzari C, Cortimiglia M, Moriondo M et al (2011) Pneumococcal DNA is not detectable in the blood of healthy carrier children by real-time PCR targeting the lytA gene. J Med Microbiol 60:710\u2013714","journal-title":"J Med Microbiol"},{"key":"6137_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/INF.0000000000001772","volume":"37","author":"J Murphy","year":"2018","unstructured":"Murphy J, O\u2019Rourke S, Corcoran M et al (2018) Evaluation of the clinical utility of a real-time PCR assay for the diagnosis of Streptococcus pneumoniae bacteremia in children. Pediatr Infect Dis J 37:153\u2013156","journal-title":"Pediatr Infect Dis J"},{"key":"6137_CR37","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s10096-011-1468-7","volume":"31","author":"L Selva","year":"2012","unstructured":"Selva L, Ciruela P, Esteva C et al (2012) Serotype 3 is a common serotype causing invasive pneumococcal disease in children less than 5 years old, as identified by real-time PCR. Eur J Clin Microbiol Infect Dis 31:1487\u20131495","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"6137_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1055\/s-0040-1702925","volume":"15","author":"A Sol\u00e9-Ribalta","year":"2020","unstructured":"Sol\u00e9-Ribalta A, de Sevilla MF, Moraga-Llop F et al (2020) Epidemiological, clinical, and microbiological characteristics of serotype-3 Streptoccocus pneumoniae infection after a partial introduction of the 13-valent pneumococcal conjugate vaccine: a prospective observational study. J Pediatr Infect Dis 15:169\u2013175","journal-title":"J Pediatr Infect Dis"},{"key":"6137_CR39","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/INF.0000000000001041","volume":"35","author":"F Moraga-Llop","year":"2016","unstructured":"Moraga-Llop F, Garcia-Garcia J-J, D\u00edaz-Conradi A et al (2016) Vaccine failures in patients properly vaccinated with 13-valent pneumococcal conjugate vaccine in Catalonia, a region with low vaccination coverage. Pediatr Infect Dis J 35:460\u2013463","journal-title":"Pediatr Infect Dis J"},{"key":"6137_CR40","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1542\/peds.2009-3027","volume":"126","author":"SH Yeh","year":"2010","unstructured":"Yeh SH, Gurtman A, Hurley DC et al (2010) Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 126:e493\u2013e505","journal-title":"Pediatrics"},{"key":"6137_CR41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/INF.0b013e318233049d","volume":"31","author":"OG Vanderkooi","year":"2012","unstructured":"Vanderkooi OG, Scheifele DW, Girgenti D et al (2012) Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J 31:72\u201377","journal-title":"Pediatr Infect Dis J"},{"key":"6137_CR42","unstructured":"European Commission Approves Pfizer\u2019s PREVENAR 20\u00ae to Help Protect Infants and Children Against Pneumococcal Disease, https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/european-commission-approves-pfizers-prevenar-20r-help. Accessed 13 Aug 2024"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06137-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06137-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06137-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T16:03:49Z","timestamp":1746893029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06137-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["6137"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06137-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5423418\/v1","asserted-by":"object"}]},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complies with the principles of the Declaration of Helsinki and the legal structure with respect to international human rights and biomedicine and the protection of personal data laws. The study was approved by the Ethics Committee of Fundaci\u00f3 Sant Joan de D\u00e9u (PIC- 157\u201317).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent, signed by the parents or legal guardians, was obtained for all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"323"}}